PMID- 37102767
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230706
IS  - 2471-254X (Electronic)
IS  - 2471-254X (Linking)
VI  - 7
IP  - 5
DP  - 2023 May 1
TI  - Prevalence of alcohol-associated liver disease: a systematic review and 
      meta-analysis.
LID - 10.1097/HC9.0000000000000133 [doi]
LID - e0133
AB  - BACKGROUND: Alcohol-associated liver disease (ALD) is a common cause of morbidity 
      and premature mortality. To date, there has been no systematic synthesis of the 
      prevalence of ALD. This systematic review was done with the aim of reporting the 
      prevalence of ALD across different health care settings. METHODS: PubMed and 
      EMBASE were searched for studies reporting the prevalence of ALD in populations 
      subjected to a universal testing process. Single-proportion meta-analysis was 
      performed to estimate the prevalence of all ALD, alcohol-associated fatty liver, 
      and alcohol-associated cirrhosis, in unselected populations, primary care, and 
      among patients with alcohol-use disorder (AUD). RESULTS: Thirty-five studies were 
      included reporting on 513,278 persons, including 5968 cases of ALD, 18,844 cases 
      of alcohol-associated fatty liver, and 502 cases of alcohol-associated cirrhosis. 
      In unselected populations, the prevalence of ALD was 3.5% (95% CI, 2.0%-6.0%), 
      the prevalence in primary care was 2.6% (0.5%-11.7%), and the prevalence in 
      groups with AUD was 51.0% (11.1%-89.3%). The prevalence of alcohol-associated 
      cirrhosis was 0.3% (0.2%-0.4%) in general populations, 1.7% (0.3%-10.2%) in 
      primary care, and 12.9% (4.3%-33.2%) in groups with AUD. CONCLUSIONS: Liver 
      disease or cirrhosis due to alcohol is not common in general populations and 
      primary care but very common among patients with coexisting AUD. Targeted 
      interventions for liver disease such as case finding will be more effective in 
      at-risk populations.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Association for the Study of Liver Diseases.
FAU - Amonker, Sachin
AU  - Amonker S
AD  - School of Medicine, University of Leeds, Leeds, UK.
FAU - Houshmand, Aryo
AU  - Houshmand A
AD  - School of Medicine, University of Leeds, Leeds, UK.
FAU - Hinkson, Alexander
AU  - Hinkson A
AD  - Leeds Liver Unit, St James's University Hospital, Leeds Teaching Hospitals NHS 
      Trust, Leeds, UK.
FAU - Rowe, Ian
AU  - Rowe I
AD  - Leeds Liver Unit, St James's University Hospital, Leeds Teaching Hospitals NHS 
      Trust, Leeds, UK.
AD  - Leeds Institute for Data Analysis, University of Leeds, Leeds, UK.
FAU - Parker, Richard
AU  - Parker R
AUID- ORCID: 0000-0003-3796-0198
AD  - Leeds Liver Unit, St James's University Hospital, Leeds Teaching Hospitals NHS 
      Trust, Leeds, UK.
AD  - Leeds Institute for Medical Research at St James's, University of Leeds, Leeds, 
      UK.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230426
PL  - United States
TA  - Hepatol Commun
JT  - Hepatology communications
JID - 101695860
SB  - IM
MH  - Humans
MH  - Prevalence
MH  - *Liver Diseases, Alcoholic/epidemiology
MH  - Liver Cirrhosis, Alcoholic/epidemiology
MH  - Liver Cirrhosis/epidemiology
MH  - *Fatty Liver, Alcoholic/epidemiology
MH  - *Alcoholism/complications/epidemiology
PMC - PMC10146123
COIS- Richard Parker consults for Durect and advises Novo Nordisk. The remaining 
      authors have no conflicts to report.
EDAT- 2023/04/27 12:42
MHDA- 2023/05/01 06:42
PMCR- 2023/04/26
CRDT- 2023/04/27 09:43
PHST- 2023/02/07 00:00 [received]
PHST- 2023/03/01 00:00 [accepted]
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/27 12:42 [pubmed]
PHST- 2023/04/27 09:43 [entrez]
PHST- 2023/04/26 00:00 [pmc-release]
AID - 02009842-202305010-00016 [pii]
AID - 10.1097/HC9.0000000000000133 [doi]
PST - epublish
SO  - Hepatol Commun. 2023 Apr 26;7(5):e0133. doi: 10.1097/HC9.0000000000000133. 
      eCollection 2023 May 1.